Pearce IP BioBlast: w/e 20 Mar 2020

Significant biosimilar activities this week include:

• On 16 March 2020, Teva and Celltrion launched Herzuma (trastuzumab) in the US. Herzuma is indicated for the treatment of breast cancer, metastatic breast cancer and metastatic gastric cancer.

• On 19 March 2020, the Centre for Biosimilars reported on a pair of biosimilar bills which were introduced to the US Congress in the 2 weeks prior. These bills include a 'shared savings' model designed to encourage physicians to switch patients to biosimilars, and a program that would allow $0 co-pays for seniors prescribed biosimilars.